Lack of association between the risk of prostate cancer and vitamin D receptor Bsm I polymorphism: a meta-analysis of 27 published studies
Authors Kang S, Zhao Y, Wang L, Liu J, Chen X, Liu X, Shi Z, Gao W, Cao F
Received 16 April 2018
Accepted for publication 20 May 2018
Published 1 August 2018 Volume 2018:10 Pages 2377—2387
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Harikrishna Nakshatri
Shaosan Kang,1,* Yansheng Zhao,2,* Lei Wang,1 Jian Liu,1 Xi Chen,1 Xiaofeng Liu,3 Zhijie Shi,4 Weixing Gao,1 Fenghong Cao1
1Department of Urology, North China University of Science and Technology Affiliated Hospital, Tangshan 063000, People’s Republic of China; 2Department of Imaging, Kailuan General Hospital, Tangshan 063000, People’s Republic of China; 3Department of Surgery, Laoting Traditional Chinese Medicine Hospital, Tangshan 063600, People’s Republic of China; 4Department of Urology, Tangshan Gongren Hospital, Tangshan 063000, People’s Republic of China
*These authors contributed equally to this work
Background: The association between vitamin D receptor gene Bsm I (rs1544410) polymorphism and prostate cancer (PCa) risk has been investigated by numerous previous studies, which yielded inconsistent results. We conducted this meta-analysis to derive a relatively precise description of this association.
Methods: All studies published up to December 2017 were identified via a systematic search of PubMed, Embase, and China National Knowledge Infrastructure databases. Pooled odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated to describe the strength of the relationship between Bsm I and PCa risk.
Results: In this meta-analysis, 27 studies with 9,993 cases and 9,345 controls were included. The pooled results revealed that Bsm I polymorphism was not associated with PCa risk in the overall analysis. Moreover, no significant relationship was found in the subgroup analyses by ethnicities, genotyping methods, Hardy–Weinberg equilibrium status, and Gleason score. In the stratified analysis by the source of controls and clinical stages, controls of benign prostatic hyperplasia (BPH) seemed to be in the particular groups in which the association of PCa risk with Bsm I polymorphism was significant (Bb vs. bb: OR=0.643, 95% CI=0.436–0.949, p=0.026; BB/Bb vs. bb: OR=0.627, 95% CI=0.411–0.954, p=0.029; B vs. b: OR=0.715, 95% CI=0.530–0.965, p=0.029).
Conclusion: Our results suggest that Bsm I polymorphism is weakly associated with PCa risk, and hence, it cannot be considered as a predictor of the occurrence and development of PCa in clinical practice. Future studies with a larger number of samples are needed to verify our results.
Keywords: Bsm I, prostate cancer, vitamin D receptor, polymorphisms, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]